Melanoma Clinical Trial
Official title:
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors
Background: cellular immunotherapy with dendritic cells (DC) loaded with tumor antigens has
shown clinical activity, although in a small number of patients. Therefore, is is mandatory
to improve the results of this strategy and to closely monitor immunologic response and cell
migration in order to improve our understanding of mechanisms of action and to settle future
fields of development..
Objectives: Primary: to confirm clinical activity of this strategy, determining tumor
response (RECIST criteria). Secondary: to determine: (1) safety; (2) antitumoral immune
response and (3) DC migration in the organism
Methodology: phase II trial in patients with advanced renal cell carcinoma and melanoma. We
will perform repeated immunizations with DC loaded with the patient´s tumor.
Background: cellular immunotherapy with dendritic cells (DC) loaded with tumor antigens has
shown clinical activity, although in a small number of patients. Therefore, is is mandatory
to improve the results of this strategy and to closely monitor immunologic response and cell
migration in order to improve our understanding of mechanisms of action and to settle future
fields of development..
Objectives: Primary: to confirm clinical activity of this strategy, determining tumor
response (RECIST criteria). Secondary: to determine: (1) safety; (2) antitumoral immune
response (through study of delayed hypersensitivity; ELISPOT; activity of Natural Killer
cells; and serum cytokine concentrations); and (3) DC migration in the organism, by labeling
with 111-Indium oxinate
Methodology: phase II trial in patients with advanced renal cell carcinoma and melanoma. We
will perform repeated immunizations with mature DC loaded with autologous tumor. We will
introduce the following novel elements to enhance efficacy (1) Pre-treatment with
cyclophosphamide to reduce regulatory / suppressor T cells; (2) maturation/activation of DC
induced by TNF-alfa, IFN-alfa and double stranded RNA (GMP-manufactured poly I:C), aimed at
replication of the phenomena observed during a viral infection (3) intranodal DC
administration in inguinal lymph nodes (4) four daily doses (repeated every 24 hours) in two
cycles one month apart (5) scintigraphic follow-up of a tracing dose of 111-In labelled DC
and (6) ) systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|